Titan Pharmaceuticals Inc
TTNPDelisted Oct 2, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000910267
Titan Pharmaceuticals Inc was delisted on Oct 2, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 18 institutions reported holding it in 13F filings for Q3 2025, worth $107.1K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Titan Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Titan Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ben-Tzvi Avraham | Director | 0 | Oct 8, 2025 | 1 |
| Choong Choon Hau | 10% Owner | 3,802,100 | Mar 27, 2024 | 0 |
| Natan David | Director | 66,250 | Oct 26, 2023 | 0 |
| Beebe Katherine | President and COO | 66,250 | Oct 26, 2023 | 0 |
| McMurdo Matthew Charles | Director | 66,250 | Oct 26, 2023 | 0 |
| Greenberg Eric Howard | Director | 66,250 | Oct 26, 2023 | 0 |
| Lazar David E. | Chief Executive Officer | 100,000 | Jul 31, 2023 | 0 |
| Chasey Peter Louis | Director | 50,000 | Jul 31, 2023 | 0 |
| Activist Investing LLC | Other: Member of 10% owner group | 0Indirect | Jun 28, 2023 | 0 |
| McNab James R | Director | 51,021Indirect | Jan 28, 2022 | 0 |
| Macfarlane M David | Director | – | Jan 5, 2022 | 0 |
| Akers Joseph A | Director | – | Jan 5, 2022 | 0 |
| Rubin Marc | Executive Chairman | – | Jan 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2023 (view filing)4:14 PM ET | Jun 21 | 7 days | Lazar David E. and 1 otherChief Executive Officer | SSaleCommon Stock, par value $0.001 | −3.39M | $1.23 | −$4.17M | −100.0%0 after | Amended |
| Jun 28, 2023 (view filing)4:14 PM ET | Jun 21 | 7 days | Lazar David E. and 1 otherChief Executive Officer | SSaleCommon Stock, par value $0.001 | −359.1K | $1.23 | −$441.7K | −100.0%0 after | Amended |
| Jan 26, 2023 (view filing)1:05 PM ET | Jan 24-25 | 2 days | Lazar David E. and 1 otherChief Executive Officer | PPurchaseCommon Stock, par value $0.001 | +57.5K | $0.9789 | +$56.3K | +1.7%3.39M after | 2 lots |
| Jul 8, 2022 (view filing)6:00 PM ET | Jul 6-7 | 2 days | Activist Investing LLC and 1 otherOther: Member of 10% owner group | PPurchaseCommon Stock, par value $0.001 | +1.91M | $0.859 | +$1.64M | +134.4%3.33M after | 2 lots |
| Jul 8, 2022 (view filing)6:00 PM ET | Jul 6 | 2 days | Activist Investing LLC and 1 otherOther: Member of 10% owner group | PPurchaseCommon Stock, par value $0.001 | +315.9K | $0.8926 | +$282.0K | +732.2%359.1K after |